NHS risks losing revenue without data strategy
Think tank Reform has warned that the National Health Service risks losing out on huge potential revenue in the future if it does not put in place a strategy to capitalise on the increasing value of its medical data.
Read on PharmaTimes
Roche’s Daniel O’Day to become Gilead's chief executive
Gilead Sciences has announced that Daniel O'Day, the current CEO of Roche's pharmaceutical unit, will become their chief executive effective from March 1 next year. Daniel will replace current CEO John Milligan, after Gilead revealed that John will step down at the end of 2018.
Read on PharmaTimes
AI app decreases symptoms of COPD, study finds
A new clinical study has found that Kaia Health’s artificial intelligence app successfully decreases symptoms of Chronic Obstructive Pulmonary Disease (COPD).
Read on PharmaTimes
SMC accepts four medicines for NHS use
Roche’s Perjeta, a medicine used to treat early stage breast cancer, has been accepted by the Scottish Medicines Consortium (SMC) for use on the NHS in Scotland.
Read on PharmaTimes
Health secretary orders review overprescribing
Health secretary Matt Hancock has ordered a review of patients who take multiple medicines, to ensure they are receiving the most appropriate treatment for their needs, and avoid needless overprescribing.
Read on PharmaTimes
1
2
3
Next
